stockrowViridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.
- Revenue
- −63.5%
- EPS
- −5.00%
- Free cash flow
- −9.92%
- Total debt
- +1,064.9%
Quarter to September 2026, against a year earlier
Follow VRDN
Alert me
Viridian Therapeutics, Inc. (VRDN) Operating cash flow
Viridian Therapeutics, Inc.'s operating cash flow for fiscal 2025 was −$276.4M, compared with −$232.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$341.5M. Over the past ten years it has ranged from −$276.4M (fiscal 2025) to −$6.9M (fiscal 2015) — the current reading is the lowest in ten years. Operating cash flow has fallen for 5 consecutive fiscal years. Viridian Therapeutics, Inc. ranks 577th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$276.4M | — |
| FY2024 | −$232.3M | — |
| FY2023 | −$184.2M | — |
| FY2022 | −$93.8M | — |
| FY2021 | −$54.6M | — |
| FY2020 | −$29.8M | — |
| FY2019 | −$36.1M | — |
| FY2018 | −$26.8M | — |
| FY2017 | −$28.2M | — |
| FY2016 | −$14.8M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$92.8M | — |
| Jun 2026 | −$105.3M | — |
| Mar 2026 | −$119.7M | — |
| Dec 2025 | −$23.8M | — |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | $51.9M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $49.9M |
| ELVN Enliven Therapeutics, Inc. compare | −$66.9M |
| CELC Celcuity, Inc. compare | −$191.7M |
| VRDN Viridian Therapeutics, Inc. | −$341.5M |
| IDYA IDEAYA Biosciences, Inc. compare | −$347.4M |
| DNLI Denali Therapeutics Inc. compare | −$444.2M |
| VKTX Viking Therapeutics, Inc. compare | −$462.6M |
| DYN Dyne Therapeutics, Inc. compare | −$477.8M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on VRDN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement